How have HUMAW shares performed in 2024?

Humacyte's stock was trading at $0.4159 at the beginning of 2024. Since then, HUMAW stock has increased by 37.1% and is now trading at $0.57. View the best growth stocks for 2024 here .

Are investors shorting Humacyte?

Humacyte saw a decline in short interest in April. As of April 15th, there was short interest totaling 4,300 shares, a decline of 18.9% from the March 31st total of 5,300 shares. Based on an average daily trading volume, of 16,200 shares, the short-interest ratio is presently 0.3 days. View Humacyte's Short Interest .

How do I buy shares of Humacyte?

Shares of HUMAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:HUMAW

Humacyte (HUMAW) Stock Price, News & Analysis

→ Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad)

Free HUMAW Stock Alerts

$0.57

-0.04 (-6.56%)

(As of 04/26/2024 ET)

Compare

Today's Range: $0.56
▼
$0.62
50-Day Range: $0.50
▼
$0.92
52-Week Range: $0.35
▼
$1.20

Volume: 13,604 shs
Average Volume: 16,368 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Ownership SEC Filings Short Interest Social Media

Get Humacyte alerts:

Ad Stansberry Research

Move Your Money Before May 22

The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

About Humacyte Stock (NASDAQ:HUMAW)

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

HUMAW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HUMAW Stock News Headlines

April 25, 2024 | americanbankingnews.com

Humacyte (NASDAQ:HUMAW) Trading Up 6.5%

See More Headlines

Receive HUMAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:HUMAW
CUSIP: N/A
CIK: 1818382
Web: www.humacyte.com
Phone: 919-313-9633
Fax: N/A
Employees: 183
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Laura E. Niklason M.D. (Age 61)
Ph.D., Founder, President, CEO & Director
Comp: $717.85k
Mr. Dale A. Sander (Age 64)
CFO, Chief Corporate Development Officer & Treasurer
Comp: $667.45k
Dr. Shamik J. Parikh M.D. (Age 51)
Chief Medical Officer
Comp: $514.72k
Dr. Juliana L. Blum Ph.D.
Co-Founder & Executive Advisor
Dr. Heather Ledbetter Prichard Ph.D. (Age 46)
Chief Operating Officer
Comp: $576.44k
Ms. Sabrina Osborne
Executive Vice President of Business Strategy & People
Mr. William John Scheessele (Age 52)
Chief Commercial Officer
Mr. Harold Alterson
Senior Vice President of Quality
Dr. Yang Cao M.D. (Age 58)
Ph.D., Chief Regulatory Officer

Key Competitors

View All Competitors

HUMAW Stock Analysis - Frequently Asked Questions

How have HUMAW shares performed in 2024?: Humacyte's stock was trading at $0.4159 at the beginning of 2024. Since then, HUMAW stock has increased by 37.1% and is now trading at $0.57.
View the best growth stocks for 2024 here.
Are investors shorting Humacyte?: Humacyte saw a decline in short interest in April. As of April 15th, there was short interest totaling 4,300 shares, a decline of 18.9% from the March 31st total of 5,300 shares. Based on an average daily trading volume, of 16,200 shares, the short-interest ratio is presently 0.3 days.
View Humacyte's Short Interest.
How do I buy shares of Humacyte?: Shares of HUMAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HUMAW) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial